BRD9
Overview
BRD9 encodes a bromodomain-containing subunit of the non-canonical BAF (ncBAF) chromatin remodeling complex. In cancer genomics, BRD9 is notable as a reported target of SF3B1-driven mis-splicing in uveal melanoma, providing cross-disease context for understanding how SF3B1 mutations exert their oncogenic effects in different tumor types.
Alterations observed in the corpus
- Discussed as a cross-disease comparison target of SF3B1-driven mis-splicing in uveal melanoma; in CLL, SF3B1-K700E instead targets NFATC1 splicing to activate mTORC1/MYC rather than BRD9 — illustrating disease-context dependence of SF3B1 splicing targets PMID:26200345
- p.Gln479His (PolyPhen2=0.99) and p.His467_Leu468del mutations in Sézary syndrome/CTCL; encodes a SWI/SNF complex component PMID:26551667
Cancer types (linked)
- CLLSLL: cross-disease comparison context; BRD9 not directly altered in CLL but cited to illustrate pan-tumor SF3B1 splicing heterogeneity PMID:26200345
Co-occurrence and mutual exclusivity
- Disease-context dependence noted: SF3B1-K700E targets BRD9 (uveal melanoma), PPP2R5A (PDAC), MAP3K7/IRAK4 (MDS), and NFATC1 (CLL) — distinct targets in different cancers PMID:26200345
Therapeutic relevance
- No direct therapeutic associations identified in this corpus.
Open questions
- Whether SF3B1 splicing modulator strategies (e.g., H3B-8800) should be tailored based on disease-specific splicing targets (BRD9 in UVM vs NFATC1 in CLL) is an open question PMID:26200345
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:26551667
This page was processed by crosslinker on 2026-05-14.